Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Lumen Technologies Inc (LUMN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Lumen Technologies Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $302.38 (market cap $39.89B), while Lumen Technologies Inc trades at $6.72 (market cap $6.93B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 5.8× Lumen Technologies Inc's market cap, and Lumen Technologies Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | LUMN | |
|---|---|---|
Market Cap | $39.89B | $6.93B |
Sector | Health | Media |
52-Week High | $491.22 | $11.83 |
52-Week Low | $278.09 | $3.70 |
Enterprise Value | $38.15B | $18.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
LUMN trades at $6.73, down 0.3% on the day, with a bearish technical signal but oversold RSI readings. The company reported a net loss of -$1.74B for 2025, though revenue remains substantial at $12.40B. Recent news highlights the acquisition of Alkira to bolster AI-era networking capabilities and cost-saving initiatives targeting $1B annually by 2027. Debt levels are high at $17.49B long-term, but leverage is trending downward.
The outlook is mixed: positive catalysts include strategic acquisitions and cost reductions, but persistent losses and high debt pose significant risks. Analyst consensus is cautious with a Hold rating predominating, though the $8.25 price target suggests modest upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →
